Evidence map›Paper›PMID 42753678›Full record

ArticleJACC. Basic to translational science2026

A Novel Triglyceride- and Cholesterol-Enriched Lipoprotein(a) Phenotype in Moderate Hypertriglyceridemia: Reversal by ApoC-III Inhibition.

Lizhu Lin, Maiah N Brush, C Bradley Nelson, Veronica J Alexander, Shuting Xia, Philip L S M Gordts, Sotirios Tsimikas

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03385239 (A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03385239 phase2completednot on this map

A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at a High Risk for CVD

TypeinterventionalSponsorAkcea TherapeuticsRan2018 to 2020Enrolled114ConditionsHypertriglyceridemia, Cardiovascular DiseasesArmsISIS 678354, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lizhu LinDivision of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
Maiah N BrushUniversity of Utah Molecular Medicine Program, Salt Lake City, Utah, USA; Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
C Bradley NelsonUniversity of Utah Molecular Medicine Program, Salt Lake City, Utah, USA; Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Veronica J AlexanderIonis Pharmaceuticals, Carlsbad, California, USA.
Shuting XiaIonis Pharmaceuticals, Carlsbad, California, USA.
Philip L S M GordtsUniversity of Utah Molecular Medicine Program, Salt Lake City, Utah, USA; Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA; Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
Sotirios TsimikasDivision of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, California, USA; Ionis Pharmaceuticals, Carlsbad, California, USA. Electronic address: stsimikas@health.ucsd.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In moderate hypertriglyceridemia, lipoprotein(a) (Lp[a]) particles were enriched in triglycerides and cholesterol, accounting for about 16% to 21% of plasma triglycerides and about 9% to 11% of plasma cholesterol. In a phase 2 trial, apolipoprotein C-III inhibition with olezarsen reduced Lp(a)-associated triglycerides and cholesterol by about 56% to 70%, with no consistent reduction in plasma Lp(a). Oxidized phospholipid measures tracked more closely with Lp(a) particle concentration than with Lp(a)-associated lipid content, supporting partially distinct dimensions of Lp(a) biology. These findings identify Lp(a) lipid composition as a dynamic, therapeutically modifiable feature in hypertriglyceridemia. (Study of ISIS 678354 [AKCEA-APOCIII-LRx] in Participants With Hypertriglyceridemia and Established Cardiovascular Disease [CVD]; NCT03385239).

Indexed as

ApoC-IIIcholesterollipoprotein(a)triglycerides

Identifiers

PMID42753678
PMCPMC13602249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.